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Abstract
Background: This study investigated the therapeutic effects of hyperbaric oxygen in experimental acute distal colitis
focusing on its effect on the production of pro-inflammatory cytokines, nitric oxide and hypoxia-inducible factor
1alpha.
Methods: Colitis was induced with a rectal infusion of 150 mg/kg of TNBS under anesthesia with Ketamine (50 mg/
kg) and Xylazine (10 mg/kg). Control animals received only rectal saline. After colitis induction, animals were subjected
to two sessions of hyperbaric oxygen and were then euthanized. The distal intestine was resected for macroscopic
analysis, determination of myeloperoxidase activity, western-blotting analyses of inducible nitric oxide synthase and
cyclooxygenase-2 expression and immunohistochemical analysis of hypoxia-inducible factor 1alpha and
cyclooxygenase-2. Cytokines levels in the distal intestine were measured using an enzyme-linked immunosorbent
assay.
Results: Hyperbaric oxygen therapy attenuated the severity of acute distal colitis, with reduced macroscopic
damage score. This effect was associated with prevention in the increase of pro-inflammatory cytokine production;
myeloperoxidase activity, in the expression of inducible nitric oxide synthase and cyclooxygenase-2. Finally, hyperbaric
oxygen inhibited the acute distal colitis-induced up-regulation of hypoxia-inducible factor 1alpha.
Conclusions: The results indicate that hyperbaric oxygen attenuates the severity of acute distal colitis through the
down-regulation of pro-inflammatory events.
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Background
The etiology of inflammatory bowel disease (IBD), in-
cluding Ulcerative colitis (UC) and Crohn’s disease (CD),
is still unknown and most likely involves a complex
interaction of genetic, environmental, and immune regu-
latory factors [1-3]. It is proposed that hypoxia and an
inappropriate mucosal immune response to normal
intestinal constituents are key factors that lead to an
imbalance in local pro- and anti-inflammatory cytokines,
including a high concentration of tumor necrosis factor-
alpha (TNF-α) and interleukin-1 beta (IL-1β) and
increased expression of hypoxia-inducible factor 1alpha
(HIF-1α) [1,4-6].
The protein encoding HIF-1α has been proposed in
the pathogenesis of IBD. It plays an essential role in the
cellular and systemic responses to hypoxia. In inflamed
mucosa, the oxygen supply is insufficient, which is due
to vasculitis and increased oxygen consumption by the
inflammatory infiltrate. This low oxygen tension results
in HIF-1α stabilization and the activation of the hypoxic
adaptive response [7].
In the context of inflammatory diseases, hypoxia has
been shown to activate multiple inflammatory mecha-
nisms that are associated with inflammation [8]. Initial
observations have indicated that colonic epithelia
become severely oxygen deprived during inflammation
[9]. Because ulceration and regeneration of the intestinal
epithelium occur during the course of the disease, an in-
creased cell metabolism is integral to the pathology of
IBD [10]. HIF-1α also controls the aspects of
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inflammation, including swelling of injured tissues and
leukocyte infiltration [11]. The contribution of each of
the mediators (pro-inflammatory cytokines, HIF-1α) to
the inflammatory cascade remains unknown, but it is
conceivable that free radicals and nitric oxide (NO),
stimulated by cytokines and HIF-1α, are the final agents
responsible for the infliction of tissue damage [7,12].
Evolving therapies for IBD have been promising over
the last decade, but some cases still require alternative
drugs and supportive therapies. This constant search for
new and more effective treatment modalities has gener-
ated some promising approaches, such as hyperbaric
oxygen (HBO) therapy. A routine HBO therapy consists
of the intermittent inhalation of 100% oxygen at pres-
sures greater than those at sea level. Oxygen inhaled at
pressures greater than room air pressure dissolves in
plasma [13].
There are reports showing that HBO therapy is effective
for the treatment of experimental colitis by of trinitroben-
zenesulfonic acid–ethanol (TNBS) [12,14,15] and as an
adjunctive therapy for healing perianal manifestations of
CD [16-18] and UC [19-21]. Despite being beneficial in
IBD, the mechanisms responsible for its therapeutic
effects have not been elucidated. Thus, the aim of the
present study was to investigate the therapeutic effects of
HBO on experimentally induced acute distal colitis focus-
ing on its effect on the production of pro-inflammatory
cytokines, nitric oxide synthase and HIF-1α.
Methods
Animals
This study was approved by the Ethical Committee of
Ribeirão Preto Medical School, University of Sao Paulo
(n° 54/2009). Twenty-eight Wistar rats (male, 150–
180 g) were kept in a room with a constant temperature
of 22 ± 1°C, with a 12-h/12-h light/dark cycle and were
fed standard pellet chow and water ad libitum. The rats
were randomly divided into four groups: I- Saline rats, sub-
mitted to intracolonic infusion of saline solution (n = 7); II-
Saline/HBO rats, submitted to intracolonic infusion of sa-
line solution plus HBO treatment (n = 7); III- TNBS rats,
submitted to intracolonic infusion of TNBS (n = 7); IV-
TNBS/HBO rats, submitted to intracolonic infusion of
TNBS plus HBO treatment (n = 7).
Induction of colitis
After overnight fasting, distal colitis was induced under
light intramuscular anesthesia with 50 mg/kg of Ketamine
(Ketalar, Aché Laboratory and Pharmacy, Guarulhos, São
Paulo, Brazil) and 10 mg/kg of Xylazine (Dopaser, Calier
S.A, Barcelona, Spain) by means of an intrarectal admin-
istration of 1 ml of TNBS (Sigma-Aldrich, Deisenhofen,
Germany) solution (150 mg/kg) dissolved in 50% ethanol,
using an 4 cm-long cannula. Comparisons were carried
out with rats that were administered an equal volume
(1 ml) of saline solution (Saline and Saline/HBO) as
described by other authors [22,23].
Hyperbaric oxygen
HBO was performed immediately after the induction of
colitis and 24 hours after in the Saline/HBO and TNBS/
HBO groups. Each session consisted of an exposure of
100% HBO at 2 atmosphere (ATM) for 120 min. Animals
in the Saline and TNBS groups remained in the chamber
during the time corresponding to a session but were not
pressurized.
Operative technique
After the second HBO session, the rats underwent lapar-
otomy, and the distal colonic segments were taken 6 cm
proximal to the anus. The colonic segments were
excised longitudinally, rinsed with saline buffer, placed
on an ice-cold plate, cleaned of fat and mesentery, and
blotted on filter paper. Then, the distal colon was
divided in four parts of full-thickness segments of 1 cm
on its longitudinal axis. The first segment was used to
determine the myeloperoxidase activity (MPO). The sec-
ond segment was used to evaluate tissue cytokines. The
third segment was used for Western blotting. The fourth
segment was used for immunohistochemistry. After
colon excision, all the animals were euthanized by over-
dose of Ketamine/Xylazine anesthesia. A flow-chart of
the experiment is presented in Figure 1.
Macroscopic analysis
Macroscopic damage score was performed according the
scale previously used for experimental colitis by Gulec
et al. [24] (Table 1). A pathologist, without prior know-
ledge regarding the treatment protocols, examined the
6 cm long distal colon segment immediately after lapar-
otomy to evaluate if there was any focal, multifocal or
diffuse ulcer and necrosis. This macroscopic scoring was
performed in each rat.
Determination of tissue myeloperoxidase activity
Neutrophil accumulation in the colon tissue of rats was
evaluated by assaying myeloperoxidase (MPO) activity.
Tissue MPO activity was determined as described by
Krawisz et al. [25]. Briefly, the tissue samples (250- to
500-mg) were homogenized in 10 vol of cold-potassium
buffer (20 mmol/l K2HPO4, pH 7.4). Then, the hom-
ogenate was centrifuged at 2000 g for 15 min at 4°C.
The pellet was re-homogenized with an equivalent vol-
ume of 50 mmol/l K2HPO4 containing 0.5% (w/v)
hexadecyltrimethyl-ammonium hydroxide. MPO activity
in the suspended pellet was assayed by measuring the
change in absorbance at 450 nm using a reading solution
(5 mg O-dianisidine; 15 μL of 1% H2O2; 3 ml phosphate
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buVer; 27 ml H2O). The change in absorbance was re-
corded and plotted on a standard curve of the neutro-
phil density, with the obtained data expressed as
myeloperoxidase activity (neutrophils/mg of tissue).
Determination of tissue cytokines concentration
The IL-1β, cytokine-induced neutrophil chemoattractant-
1 (CINC-1), interleukin-10 (IL-10) and TNF-α levels were
quantified in the colon tissues as described previously
[26] by using a commercially available enzyme-
immunometric assay (ELISA) kit (R&D Systems,
Minneapolis USA). The specimen was stored at −70°C
until it was required for assay. In brief, the colon spec-
imens were dissected, frozen with liquid nitrogen,
crushed in a mortar and pestle, solubilized in phos-
phate buffered saline (PBS) and measured using
ELISA, with the results expressed as picograms per
milliliter for each cytokine. As a control, the
concentration of each cytokine was determined in the
Saline group.
Western blotting analysis
The specimens were stored at −70°C until required for
assay. Colon samples were homogenized in RIPA buffer
with a complete protease inhibitor cocktail (Roche). The
expression of cyclooxygenase-2 (COX-2; 72 kDa) and
inducible nitric oxide synthase (iNOS; 110 kDa) were
evaluated by Western blotting analysis. Briefly, the pro-
tein concentration was determined following Bradford’s
colorimetric method. Proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE-12%) and
trans blotted onto nitrocellulose membranes (Amersham
Pharmacia Biotech, Little Chalfont, UK). After blocking
with 5% dry milk (overnight), the membranes were incu-
bated with specific primary antibodies at a dilution of
1:1000 (for COX-2, Abcam, Cambridge, UK and iNOS
SIGMA-Aldrich, S. Louis, US). After 3 washes, the filter
was then incubated with the secondary horseradish
peroxidase-linked anti-goat IgG (for COX-2) and anti-
mouse IgG (for iNOS) antibodies. To check for equal
loading, the blots were analyzed for β-actin expression.
Immunodetection was performed using an enhanced
chemiluminescence light-detecting kit (Amersham Phar-
macia, Biotech, Little Chalfont, UK). Densitometric data
Figure 1 Flow-chart of experiment. All animals (n = 28) were submitted to intramuscular anesthisia (Ketamine 50 mg/kg and Xylazin 10 mg/kg),
then divided to four groups: Saline rats (n = 7): submitted to intracolonic infusion of saline solution, no chamber pressurization; Saline/HBO rats:
submitted to intracolonic infusion of saline solution plus two sessions of HBO (n = 7); TNBS rats, submitted to intracolonic infusion of TNBS and no
chamber pressurization (n = 7); TNBS/HBO rats, submitted to intracolonic infusion of TNBS plus two sessions of HBO (n = 7). After the second HBO
session all animals were submitted to intramuscular anesthesia, laparotomy, colon extraction, macroscopic damage score and the colon was divided
into four segments, of 1 cm each (First segment: MPO; Second: Cytokines; Third: Western Blot (COX-2 and iNOS); Fourth: Immunohistochemistry
(COX-2 and HIF-1α).
Table 1 The scale of macroscopic damage scoring
Macroscopic scoring parameter Score
Normal appearance 0
Focal ulcer 1
Multifocal ulcer 2
Diffuse ulcer and necrosis 3
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were measured following normalization to the control
(house-keeping gene) by Scientific Imaging Systems
(Image labTM 3.0 software, Biorad Laboratories, Hercules
CA). Data were expressed as the relative density of iNOS/
β-Actin bands and COX-2/ β-Actin bands.
Immunohistochemical analysis
Tissue samples were fixed in 4% neutral formalin and
were embedded in paraffin. Immunohistochemical stain-
ing was performed using the Biocare Medical Mach 4
Universal Polymer Detection (Concord, CA, USA) kit.
The protocol used has been described elsewhere [27].
The dilution and source of the primary antibodies used
in this study were HIF-1α (1:50, clone H1alfa67-sup,
Abcam, Cambridge, UK) and COX-2 (1:200, clone 4H12,
Novocastra®, Newcastle upon Tyne, UK). In accordance
with the literature, the immunohistochemistry study was
evaluated as follows. For HIF-1α expression, only homo-
genously and darkly stained nuclei were considered, and
cases were considered positive when more than 1% of
the colon cells were stained. The slides were evaluated
by two experienced pathologists. After immunohisto-
chemistry reactions, the slides were scanned as high-
resolution images using Aperio Scan- Scope XT (Aperio,
Vista, CA, USA). The images were then visualized using
Image Scope software (Aperio, Vista, CA, USA). COX-2
expression in the submucosa was visualized by staining
with a rabbit anti-mouse COX-2 polyclonal antibody.
The immunoreactivity was considered positive when
perinuclear and cytoplasmic cell staining for COX-2
were detected. Quantification of the positively and
negatively marked cells was then performed to establish
the ratio between these markers.
Statistical analysis
The results are presented as means ± SEM. The differ-
ences were evaluated by one-way ANOVA followed by
Bonferroni’s test (three or more groups) or Mann-
Whitney’s test (two groups). The level of significance
was set at P < 0.05.
Results
HBO ameliorates acute distal colitis: reduction in the
macroscopic damage scores
Colitis was confirmed in rats, which received an intrar-
ectal injection of TNBS. These animals presented
increased macroscopic damage scores. HBO treatment
reduced the colonic damage relative to that of the
untreated colitis group (P < 0.02). HBO therapy was
found to be effective in ameliorating the macroscopic
lesion score (Figure 2A). Examples of the distal colon
in Saline, Saline/HBO, TNBS and TNBS/HBO are
shown in (Figure 2B-E).
HBO reduces tissue myeloperoxidase activity (MPO) and
pro-inflammatory cytokine expression in acute distal
colitis
Tissue MPO activity was significantly increased in rats
with colitis (TNBS) compared to controls (P < 0.001),
and the HBO treatment (TNBS/HBO) significantly
decreased the MPO activity (P < 0.001) (Figure 3A). Rats
with colitis (TNBS) had significantly increased tissue
levels of all cytokines compared to controls (P < 0.05).
Figure 2 Hyperbaric oxygen therapy ameliorates acute distal colitis by diminishing the macroscopic damage scores. (A) Macroscopic damage
score. The results are presented as: − Normal Appearance: Score 0; − Focal ulcer: Score 1; − Multifocal ulcer: Score 2; − Diffuse ulcer and necrosis:
Score 3. (B) Intestine of control rat (Saline), normal appearance (score zero); (C) Intestine of Saline/HBO rat, normal appearance (score zero); (D)
Intestine of TNBS rat, diffuse ulceration and necrosis (Score three); (E) Intestine of rat with colitis treated with hyperbaric oxygen (TNBS/HBO) had reduced
macroscopic damage score (Score two). Values expressed as mean ± SEM. (n = 7 per group). * P < 0.02 compared to colitis group (Mann–Whitney).
Parra et al. Medical Gas Research  (2015) 5:6 Page 4 of 9
Treatment with HBO normalized IL-1β, TNF-α, CINC-1
and IL-10 (P < 0.05) in rats subjected to colitis by TNBS
(Figure 3B,C,D and E).
HBO reduces COX-2, iNOS and HIF-1α expression in acute
distal colitis
Western blotting analysis of intestinal extracts showed
that colitis rats (TNBS) had significantly increased COX-
2 and iNOS protein expression compared to controls (P
<0.01), and there was a significant decrease in the relative
density of COX-2 and iNOS protein in colitis rats treated
with HBO (TNBS/HBO) (P < 0.01) (Figure 4A and C).
The relative analysis of the COX-2, iNOS and β-actin
expression are shown in Figure 4B and D. Immunohisto-
chemical analysis of the intestinal extract showed that
TNBS rats had increased COX-2 and HIF-1α tissue
expression compared to controls (P < 0.001), and there
was a significant decrease in COX-2 (Figure 5A-E) and
HIF-1α (Figure 6A-E). in rats with colitis treated with
HBO (TNBS/HBO) (P < 0.001).
Discussion
Despite the growing number of therapeutic methods and
the recent application of new drugs for the treatment of
IBD, many patients still present with refractory symp-
toms. The HBO is an interesting therapeutic approach
although its mechanism of action is not totally clear.
The present results demonstrate effectiveness of HBO
therapy in a model of experimental acute distal colitis in
rats by decreasing tissue damage. In addition, the ex-
pression levels of major inflammatory mediators in the
damage tissue such as pro-inflammatory cytokines, HIF-
1α, iNOS and COX-2 as well as neutrophil infiltration
were found to be down-modulated by hyperbaric oxy-
genation, suggesting that they were involved in the
therapeutic effects in experimental acute colitis.
In the present study, neutrophils infiltration into intes-
tinal lesions was indirectly evaluated by the myeloperox-
idase activity assay. MPO, an enzyme found primarily
within neutrophils, is a sensitive marker for quantifying
neutrophil content in tissues. The beneficial effects of
Figure 3 Hyperbaric oxygen reduces tissue myeloperoxidase activity (MPO) and pro-inflammatory cytokine expression in acute distal colitis. (A)
Acute distal colitis was induced by an intracolonic injection of TNBS (150 mg/kg). After two sessions of hyperbaric oxygen (HBO) the rats were
killed, the distal 6 cm colonic segment was removed, and the MPO activity was measured. The anti-inflammatory effect of HBO was detected as a
decrease in the number of tissue neutrophils. (B) Colitis by TNBS increases the IL-1β tissue expression and HBO decreases its expression. (C) Colitis
by TNBS increases the TNF-α tissue expression. There was not a significant decrease in expression after HBO. (D) Colitis by TNBS increases the CINC-1
tissue expression and HBO decreases its expression. (E) Colitis by TNBS increases the IL-10 tissue expression and HBO decreases its expression.
Data are expressed as the mean ± S.E.M. (n = 6–7). Data are expressed as the mean ± S.E.M. (n = 6–7). # P < 0.05 compared to the saline-
injected group; *P < 0.05 compared to colitis (TNBS) group; (one-way ANOVA followed by the Bonferroni’s test).
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HBO may be partially attributed to its ability to reduce
neutrophil activation and sequestration in inflammatory
intestinal mucosa.
A large number of evidences have revealed that the in-
crease of oxidative stress and iNOS activity was a not-
able feature of IBD, which resulted in a pathological
cascade of free radical reactions and further yielding
more oxidative free radicals to impair the structure and
function of cell [28,29]. As we know small amounts of
NO are necessary to maintain tissue integrity. However,
hypoxia, HIF-1α and pro-inflammatory cytokines
(mainly IL-1β and TNF-α) activation leads to increased
iNOS expression and excessive NO production by mac-
rophages, resulting in tissue injury. Such damage further
enhances cytokine release by inflammatory cells in a
feedback loop, restarting the cycle [26].
Figure 4 Hyperbaric oxygen reduces tissue COX-2 and iNOS expression. (A) Acute distal colitis was induced by the intracolonic injection of TNBS
(150 mg/kg). After two sessions of hyperbaric oxygen, the rats were killed, the distal 6 cm colonic segment was removed, and the expression of
COX-2 was determined by western blot. The β-Actin level was used as a control. Data are presented as representative blots. (B) Densitometry of
the pixel intensity of COX-2 bands relative to β-Actin is present. (C) Expression of iNOS was determined by western blot. The b-actin level was
used as a control. (D) Densitometry of the pixel intensity of iNOS bands relative to β-Actin is present. Data are presented as representative blots.
Data are expressed as the mean ± S.E.M. (n = 5–7). # P < 0.01 compared to the saline-injected group; * P < 0.01 compared to colitis (TNBS) group
(one-way ANOVA followed by the Bonferroni’s test).
Figure 5 Hyperbaric oxygen reduces COX-2 expression in acute distal colitis. Acute distal colitis was induced by intracolonic injection of TNBS
(150 mg/kg). After two sessions of hyperbaric oxygen, the rats were killed, the distal 6 cm colonic segment was removed, and the expression of
COX-2 in sub mucosa was determined by immunohistochemical analysis. (A) Group I (Saline), (B) Group II (Saline/HBO), (C) Group III (TNBS), (D)
Group IV (TNBS/HBO), (E) Rats with colitis (TNBS) presented substantial up-regulation of immunofluorescence of COX-2 in the colon. The HBO
treatment (TNBS/HBO) remarkably reduces COX-2 expression. Data are expressed as the mean ± S.E.M. (n = 7). # P < 0.001 compared to the
saline-injected group; *P < 0.001 compared to colitis (TNBS) group (one-way ANOVA followed by the Bonferroni’s test).
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In this present study, COX-2 levels were higher in
TNBS-induced rats and HBO was able to reduce their
levels. It is known that abnormal metabolism of arachi-
donic acid is another vital factor in the IBD pathogen-
esis. COX-2 could be activated to produce excessive
prostaglandin E2 and thromboxane B2, two important
inflammatory mediators, in the inflammatory bowel dis-
ease, which contribute to bowel hyperemia, edema and
even dysfunction. In addition, thromboxane B2 could
also induce platelet aggregation, vasoconstriction and
microthrombosis, aggravating the inflammatory reaction
[30].
Accordingly, a possible mechanism to explain the ef-
fect of HBO therapy after TNBS-induced in rats is in-
crease tissue oxygen (consequently decreases HIF-1α)
and reduced production of IL-1β, CINC-1 and TNF-α in
the local tissue. This data are consistent with new stud-
ies that showed the correlation between an inflammatory
signals induce IL-1β through HIF-1α [31]. Therefore,
one study suggests that the reduction of IL-1β produc-
tion may play an important role in the immunosuppres-
sive effect of HBO, as shown by other authors [32].
A number of studies suggest a close association be-
tween inflammation and hypoxia at the tissue level,
resulting in increased levels of HIF-1α [3,33-39]. Herein,
it was provided evidence that HBO therapy is essential
to control the level of HIF-1α and therefore improve
colitis by TNBS-induced. Another studies from both hu-
man disease [40] and experimental colitis [34,36] suggest
the presence of colonic hypoxia and its significance in
the disease process and indicate that colonic epithelia
becomes severely oxygen deprived during inflammation
and that epithelial hypoxia in TNBS colitis is associated
with inflammatory lesions. Hypoxia cause ischemia
which could worsen the disease and to promote necro-
sis, inflammation, and ulceration in the gut. The HBO
therapy diminishes colitis activity by increasing tissue
O2 diffusion.
It was proposed that the increased levels of HIF-1α
and cytokines (such as IL-1β, TNF-α and CINC-1) con-
tributed significantly to the establishment and mainten-
ance of chronic inflammation [31,35]. We hypothesized
that TNBS colitis would result in HIF-1α activation, par-
ticularly within the epithelium, resulting in increased ex-
pression of pro-inflammatory cytokines such as IL-1β
and TNF-α, and higher levels of iNOS. We observe that
the expression of iNOS shows significant increase that
supposedly trigger by IL-1β and TNF-α. Some works
focus in demonstrate the correlation between pro in-
flammatory cytokines inducing the expression of iNOS
protein [41,42]. Increased iNOS activity and, conse-
quently, higher levels of NO, contribute to inflammation,
oxidative stress and tissue damage.
Although the present results strongly suggest that
HBO might be an interesting alternative therapy for
TNBS-induced distal colitis, there are limitations to this
study. The exactly mechanism of action of HBO was not
elucidated, spite of the results indicate evolvement of
pro-inflammatory cytokines and HIF-1α in colonic dam-
age. Measurements were performed only one time
(24 hours after colitis induction). And further work is
needed to elucidate why TNF-α concentration did not
significantly decreased in animals submitted to HBO.
Probably at the time this cytokine was measured the
Figure 6 Hyperbaric oxygen reduces HIF-1α expression in acute distal colitis. Acute distal colitis was induced by intracolonic injection of TNBS
(150 mg/kg). After two sessions of hyperbaric oxygen, the rats were killed, the distal 6 cm colonic segment was removed, and the expression of
HIF-1α was determined by immunohistochemical analysis. (A) Group I (Saline), (B) Group II (Saline/HBO), (C) Group III (TNBS), (D) Group IV (TNBS/
HBO), and (E) Rats with colitis (TNBS) presented substantial up-regulation of immunofluorescence of HIF-1α in the colon. The HBO treatment
(TNBS/HBO) remarkably reduces HIF-1α expression. Data are expressed as the mean ± S.E.M. (n = 7). # P < 0.001 compared to the saline-injected
group; *P < 0.001 compared to colitis (TNBS) group (one-way ANOVA followed by the Bonferroni’s test).
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higher amount of TNF-α was lost. It is well known that
the higher concentration is in the initial phase and after
this cytokine is rapidly degraded.
According to the medical literature and our results, we
may state the way in which hyperbaric oxygen amelio-
rates TNBS-induced acute distal colitis as follows: TNBS
induces colitis by breaking the mucosal integrity and
subsequent damage to intestinal epithelium. There is
epithelial hypoxia and induction of HIF-1α, with in-
creased expression of pro-inflammatory cytokines such
as IL-1β and TNF-α, and higher levels of iNOS. Higher
cytokine and NO levels contribute to inflammation and
oxidative stress, neutrophil infiltration which result in
mucosal damage, restarting the cycle. Hyperbaric oxygen
acts diminishing hypoxia (and HIF-1α), consequently de-
creasing cytokine expression, NO production, COX-2
and neutrophil infiltration, resulting in less damage e
amelioration of colitis.
Conclusion
The present results strongly suggest that the treatment
with HBO ameliorates TNBS-induced model of colitis
and is associated with decreased in the severity of in-
flammation as measured by MPO, cytokine levels, iNOS
and COX-2 expression. Furthermore, it is plausible to
suggest that the mechanism of the HBO therapy might
be through down-regulation of HIF-1α expression. Fur-
ther studies need to be done to prove this hypothesis.
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